<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial therapy and prognosis of community-acquired bacterial meningitis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial therapy and prognosis of community-acquired bacterial meningitis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial therapy and prognosis of community-acquired bacterial meningitis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodrigo Hasbun, MD, MPH, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan R Tunkel, MD, PhD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bacterial meningitis is a medical emergency, and immediate steps must be taken to establish the specific cause and initiate effective therapy. The mortality rate of untreated disease approaches 100 percent [<a href="#rid1">1</a>], and even with optimal therapy, it is associated with significant morbidity and mortality [<a href="#rid2">2,3</a>]. </p><p>The presence of bacterial meningitis is suggested by the symptoms of fever, altered mental status, headache, and nuchal rigidity, although one or more of these findings are absent in many patients with bacterial meningitis [<a href="#rid4">4-7</a>]. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p>The initial therapy and prognosis of community-acquired bacterial meningitis will be reviewed here. The epidemiology, pathogenesis, clinical features, diagnosis, treatment of specific pathogens, and use of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in the management of community-acquired bacterial meningitis in adults are discussed separately. (See  <a class="medical medical_review" href="/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1289.html" rel="external">"Pathogenesis and pathophysiology of bacterial meningitis"</a> and  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a> and  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p>The management of health care-associated meningitis and ventriculitis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRETREATMENT EVALUATION</span></p><p class="headingAnchor" id="H3"><span class="h2">History</span><span class="headingEndMark"> — </span>If possible, the following historical information should be obtained before antimicrobial therapy of presumed bacterial meningitis is instituted. Some aspects of the history may suggest a potential causative organism. Has the patient had or does the patient have:</p><p class="bulletIndent1"><span class="glyph">●</span>Serious drug allergies</p><p class="bulletIndent1"><span class="glyph">●</span>Recent exposure to someone with meningitis (eg, <em>Neisseria meningitidis</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>A recent or current sinusitis or otitis media (eg, <em>S. pneumoniae</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent use of antibiotics (drug-resistant <em>S. pneumoniae</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Recent travel such as to the Hajj and Umrah pilgrimage (eg, <em>N. meningitidis</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>A history of recent injection drug use (eg, <em>Staphylococcus aureus</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>A progressive petechial or ecchymotic rash (eg, <em>N. meningitidis</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>A history of recent or remote head trauma (eg, <em>S. pneumoniae</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection or risk factors (eg, <em>S. pneumoniae, Listeria monocytogenes</em>, <em>Cryptococcus neoformans</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Any other immunocompromising conditions</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Pretreatment testing</span><span class="headingEndMark"> — </span>The initial approach to management in a patient with suspected bacterial meningitis includes performance of a lumbar puncture (LP) to determine whether the cerebrospinal fluid (CSF) findings are consistent with the diagnosis  (<a class="graphic graphic_algorithm graphicRef50114" href="/d/graphic/50114.html" rel="external">algorithm 1</a>) [<a href="#rid8">8</a>]. An important early decision relates to whether a head computed tomography (CT) should be performed prior to LP.</p><p class="bulletIndent1"><span class="glyph">●</span>Although a screening CT scan is not necessary in the majority of patients, a head CT should be performed <strong>before</strong> LP in adults with suspected bacterial meningitis who have one or more of the following risk factors [<a href="#rid8">8,9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromised state (eg, HIV infection, immunosuppressive therapy, solid organ or hematopoietic cell transplantation)</p><p class="bulletIndent2"><span class="glyph">•</span>History of central nervous system (CNS) disease (mass lesion, stroke, or focal infection)</p><p class="bulletIndent2"><span class="glyph">•</span>New-onset seizure (within one week of presentation)</p><p class="bulletIndent2"><span class="glyph">•</span>Papilledema</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal level of consciousness</p><p class="bulletIndent2"><span class="glyph">•</span>Focal neurologic deficit</p><p></p><p class="bulletIndent1">If a head CT is indicated, blood cultures should be obtained immediately, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and empiric antimicrobial therapy should be started once blood cultures have been obtained and prior to head CT. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent1">If the results of the CT reveal that LP is contraindicated, therapy for bacterial meningitis should be continued (if indicated) or evaluation and treatment for an alternative diagnosis should be undertaken (ie, if the CT suggests a different cause for the patient's clinical presentation).</p><p></p><p class="bulletIndent1">In one report, adherence to these guidelines in adults with bacterial meningitis identified all patients with major intracranial abnormalities [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients <strong>without</strong> any of the risk factors described above, blood cultures and LP may be performed without performing a head CT. Obtaining a head CT scan in patients without an indication has no clinical benefit and delays lumbar puncture [<a href="#rid11">11</a>]. At the time of LP, an opening pressure should be obtained. Once CSF has been obtained (and before results are available), <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and empiric antimicrobial therapy should be initiated if bacterial meningitis is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSF should be sent for:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cell count and differential</p><p class="bulletIndent2"><span class="glyph">•</span>Glucose concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Protein concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Gram stain and bacterial culture</p><p class="bulletIndent2"><span class="glyph">•</span>Other appropriate tests, depending upon the level of concern for other etiologies of meningitis or meningoencephalitis</p><p></p><p class="bulletIndent1">Characteristic findings in bacterial meningitis include a CSF glucose concentration &lt;40 mg/dL, a CSF to serum glucose ratio of ≤0.4, a protein concentration &gt;200 mg/dL, and a white blood cell (WBC) count above 1000/microL, usually composed primarily of neutrophils [<a href="#rid2">2,8,12</a>]. (See  <a class="medical medical_review" href="/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states"</a>.)</p><p></p><p class="bulletIndent1">However, the spectrum of CSF values in bacterial meningitis is so wide that the absence of one or more of these findings is of little value  (<a class="graphic graphic_table graphicRef76324" href="/d/graphic/76324.html" rel="external">table 1</a>) [<a href="#rid4">4-6</a>]. For example, in a prospective study of 1412 adults with bacterial meningitis, a CSF WBC &gt;1000/microL was seen in only 66 percent of patients [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Cerebrospinal fluid analysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before CSF results are available, it can be difficult to know whether the patient has bacterial or viral meningitis. The decision of which tests to perform on the CSF will depend on patient-specific factors, such as those described above (see <a class="local">'History'</a> above). In addition to suggesting specific diagnostic tests, we often send an extra tube of CSF if possible to the laboratory to be held for further studies, as the CSF profile and the patient's clinical course may warrant additional testing (see <a class="local">'Negative CSF culture'</a> below). Selected viruses that can cause meningitis are summarized in the table  (<a class="graphic graphic_table graphicRef79745" href="/d/graphic/79745.html" rel="external">table 2</a>). The diagnostic approach to aseptic meningitis is presented separately. (See  <a class="medical medical_review" href="/d/html/1296.html" rel="external">"Aseptic meningitis in adults"</a>.)</p><p></p><p>The diagnosis of bacterial meningitis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">GENERAL PRINCIPLES OF THERAPY</span><span class="headingEndMark"> — </span>There are a number of general principles of therapy in patients with bacterial meningitis [<a href="#rid2">2,8</a>]. The most important initial issues are avoidance of delay in administering antimicrobial therapy and the choice of drug regimen.</p><p class="headingAnchor" id="H6"><span class="h2">Avoidance of delay</span><span class="headingEndMark"> — </span>Antimicrobial therapy, along with adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> when indicated, should be initiated as quickly as possible after the performance of the lumbar puncture (LP) or, if a CT scan of the head is to be performed before LP, as quickly as possible after blood cultures are obtained  (<a class="graphic graphic_algorithm graphicRef50114" href="/d/graphic/50114.html" rel="external">algorithm 1</a>) [<a href="#rid2">2,8</a>]. (See <a class="local">'Pretreatment testing'</a> above and  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Indications for CT scan before LP'</a> and <a class="local">'When to administer dexamethasone'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h3">Effects of delay</span><span class="headingEndMark"> — </span>Many studies have shown that a delay in the administration of antimicrobial agents can have adverse effects on mortality and residual neurological deficits [<a href="#rid5">5,13-17</a>]. As an example, in a population-based cohort study of 173 patients with community-acquired bacterial meningitis, a delay in antimicrobial treatment of more than six hours compared to treatment within two hours of admission was associated with an increase in in-hospital mortality (risk ratio [RR] 1.6, 95% CI 0.8-3.2) and unfavorable outcome at discharge (RR 1.5, 95% CI 1.0-2.2) [<a href="#rid17">17</a>]. Longer delays in antibiotic therapy were associated with mortality rates as high as 30 percent. </p><p class="headingAnchor" id="H8"><span class="h3">Causes of delay</span><span class="headingEndMark"> — </span>Important causes of delay in the initiation of antimicrobial therapy include atypical clinical presentation and delay due to cranial imaging. It is important to note that antimicrobial therapy, along with adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> therapy (if indicated), should <strong>not</strong> be delayed if imaging is performed prior to lumbar puncture.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical presentation</strong> – In the retrospective study of 119 adults with bacterial meningitis described above, the most dramatic clinical predictor of death was the absence of fever at presentation (OR 39.4, 95% CI 4.3-358.1) [<a href="#rid15">15</a>]. This finding, along with other "atypical features" (eg, lack of headache or neck stiffness), accounts for some of the delay in making the diagnosis and initiating therapy. While a deliberate delay of therapy is never warranted, the diagnosis can be quite challenging in cases with atypical features. Lowering the threshold for initiation of therapy may be prudent, but there is no clear guideline that will identify bacterial meningitis in patients with atypical features without some risk of over-treatment. (See <a class="local">'Prediction of risk'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delay due to imaging</strong> – An important cause of delayed therapy in patients with suspected bacterial meningitis is performance of a CT scan of the head to exclude an occult mass lesion or other findings that could lead to cerebral herniation during subsequent cerebrospinal fluid (CSF) removal [<a href="#rid2">2,8</a>]. Should LP be delayed by the need for cranial imaging in patients suspected of having bacterial meningitis, blood cultures should be obtained and antimicrobial agents should be administered empirically along with adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (if indicated) just prior to or concomitant with the first antibiotic dose. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent1">Although commonly performed, a screening CT scan of the head is <strong>not</strong> necessary in the majority of patients. In a study of 549 adults with community-acquired meningitis, 354 (64.8 percent) of patients without an indication underwent cranial imaging with no clinical benefit [<a href="#rid11">11</a>]. Although the use of antimicrobial therapy before LP decreases the yield of CSF Gram stain and culture in bacterial meningitis [<a href="#rid18">18,19</a>], the CSF profile is not affected and can still be utilized by clinicians to formulate their differential diagnosis. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Cerebrospinal fluid examination'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Antibiotic regimen</span></p><p class="headingAnchor" id="H13"><span class="h3">Choice of regimen</span><span class="headingEndMark"> — </span>Antimicrobial selection must be empiric immediately after CSF is obtained or when lumbar puncture is delayed. In such patients, antimicrobial therapy needs to be directed at the most likely bacteria based upon patient age and underlying comorbid disease  (<a class="graphic graphic_table graphicRef71968 graphicRef60707" href="/d/graphic/71968.html" rel="external">table 3A-B</a>) [<a href="#rid2">2,8</a>]. Knowledge of local susceptibility patterns also may be important. Empiric regimens are discussed in detail below. (See <a class="local">'Empiric regimens'</a> below.)</p><p>Once the CSF Gram stain results are available, the antimicrobial regimen should be tailored to cover the most likely pathogen. (See <a class="local">'Regimens based upon Gram stain'</a> below.)</p><p>If the CSF findings are consistent with the diagnosis of acute bacterial meningitis but the Gram stain is negative, empiric antimicrobial therapy should be continued. (See <a class="local">'Empiric regimens'</a> below.)</p><p>The antimicrobial regimen should be modified further, when indicated, based on the CSF culture and susceptibility results. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Route of administration</span><span class="headingEndMark"> — </span>Because of the general limitation in antimicrobial penetration into the CSF, all patients should be treated with intravenous antimicrobial agents. Oral antimicrobial agents should be avoided since the dose and tissue concentrations tend to be considerably lower than with parenteral agents. </p><p class="headingAnchor" id="H168234278"><span class="h3">Duration</span><span class="headingEndMark"> — </span>The duration of antimicrobial therapy for bacterial meningitis depends upon the causative pathogen. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.) </p><p class="headingAnchor" id="H627357021"><span class="h3">Pharmacologic properties</span><span class="headingEndMark"> — </span>There are three general requirements of antimicrobial therapy for bacterial meningitis [<a href="#rid2">2,20</a>]: Use of bactericidal drugs effective against the infecting organism; Use of drugs that enter the CSF, since the blood-brain barrier prevents macromolecule entry into the CSF; and Structuring the regimen to optimize bactericidal efficacy based on the pharmacodynamic characteristics of the antimicrobial agent(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bactericidal drugs</strong> – Since the CSF is a site of impaired humoral immunity, a fundamental principle of therapy of bacterial meningitis is that antimicrobial agents must achieve a bactericidal effect within CSF to result in optimal microbiologic cure [<a href="#rid2">2,20</a>]. Bactericidal antimicrobial therapy results in optimal microbiologic cure and survival in animals with pneumococcal meningitis [<a href="#rid20">20</a>]. This principle is also supported by clinical observations of poor outcomes in patients receiving bacteriostatic therapy [<a href="#rid2">2,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug entry into CSF</strong> – Antimicrobial penetration into CSF depends to a large extent on the status of the blood-brain barrier and by clearing the antimicrobial via active transport in pumps in the arachnoid villa [<a href="#rid20">20,21</a>]. When the blood-brain barrier is normal, most beta-lactam agents (eg, penicillin) penetrate poorly. However, in the presence of meningeal inflammation, CSF penetration is enhanced likely as a result of separation of intercellular tight junctions and inhibition of the organic pump, raising the levels of the antimicrobials in the CSF. As inflammation subsides, antimicrobial entry decreases and clearance of the drug increases. Thus, maximal parenteral doses should be continued throughout the course of therapy to maintain adequate CSF concentrations. Antibiotic entry is also enhanced with drugs that have a high lipid solubility, low molecular weight, low protein binding, and low ionization at physiologic pH [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states", section on 'Blood-brain barrier'</a>.)</p><p></p><p class="bulletIndent1">There are specific dosing recommendations for the antimicrobial agents used to treat bacterial meningitis in order to attain maximal concentrations in the CSF. In some cases, higher doses of agents are used for bacterial meningitis than for other infections  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacodynamics</strong> – For antimicrobial agents that exhibit time-dependent antimicrobial activity (eg, beta-lactams, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>), the bactericidal activity depends upon the time that the agent is above the minimal inhibitory concentration (MIC) as a proportion of the dosing interval [<a href="#rid22">22</a>]. For agents that exhibit concentration-dependent antimicrobial activity (eg, aminoglycosides), killing occurs over a wide range of antimicrobial concentrations and there is a prolonged recovery period (ie, the postantibiotic effect) after drug concentrations fall below the MIC during which regrowth of bacteria is delayed. The CSF pharmacodynamics of fluoroquinolones are more complicated, however, and features of both time dependency and concentration dependency have been described.</p><p></p><p class="headingAnchor" id="H3467680742"><span class="h2">When to administer dexamethasone</span><span class="headingEndMark"> — </span>As part of empiric therapy for adults in the developed world with suspected community-acquired bacterial meningitis in whom the causative organism is not yet known, we recommend administration of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. Intravenous administration of glucocorticoids (usually dexamethasone) prior to or at the time of administering antibiotics has been associated with a reduction in the rate of hearing loss, other neurologic complications, and mortality in patients with meningitis caused by <em>S. pneumoniae, </em>which is the most common cause of bacterial meningitis in adults in the developed world. The indications for dexamethasone for patients with suspected or confirmed bacterial meningitis in the developing world depend on the patient population and are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults", section on 'Developing regions'</a>.)</p><p>Adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> should be given shortly before or at the same time as the first dose of antibiotics, when indicated. Dexamethasone should be continued if the CSF Gram stain and/or the CSF or blood cultures reveal <em>S. pneumoniae</em>. <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is added to the regimen in patients with pneumococcal meningitis receiving dexamethasone if susceptibility studies show intermediate susceptibility (minimum inhibitory concentration [MIC] ≥2 mcg/mL) to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>. A detailed discussion on the use of dexamethasone for the management of bacterial meningitis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">EMPIRIC REGIMENS</span></p><p class="headingAnchor" id="H2900931484"><span class="h2">Factors impacting regimen selection</span><span class="headingEndMark"> — </span>The empiric approach to antimicrobial selection in patients with suspected bacterial meningitis is directed at the most likely bacteria based on the patient's age and host factors  (<a class="graphic graphic_table graphicRef71968 graphicRef60707" href="/d/graphic/71968.html" rel="external">table 3A-B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>) [<a href="#rid8">8,23</a>]. (See <a class="local">'No known immune deficiency'</a> below and <a class="local">'Immunocompromised patients'</a> below and <a class="local">'Beta-lactam allergy'</a> below and <a class="local">'Empiric treatment during epidemics'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causative organisms</strong> – <em>S. pneumoniae</em> followed by <em>N. meningitidis</em> are the two most commonly isolated pathogens in community-acquired bacterial meningitis, accounting for 0.306 cases and 0.123 cases per 100,000 people, respectively, in the United States [<a href="#rid24">24</a>]. In a large prospective study of 1412 episodes of community-acquired bacterial meningitis in the Netherlands, <em>S. pneumoniae</em> was responsible for 51 percent, <em>N. meningitidis</em> for 37 percent, and <em>L. monocytogenes</em> for 4 percent of cases [<a href="#rid12">12</a>]. Importantly, in adults, the incidence of bacterial meningitis caused by <em>L. monocytogenes</em> rises with increasing age [<a href="#rid25">25</a>]. For this reason, adults &gt;50 years of age should receive an antimicrobial agent with activity against <em>L. monocytogenes</em> (eg, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>) as part of the empiric regimen. (See <a class="local">'No known immune deficiency'</a> below.) </p><p></p><p class="bulletIndent1">More detailed discussions of the epidemiology of bacterial meningitis in adults and children are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults", section on 'Incidence'</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of specific agents </strong>– There have been no randomized trials in adults regarding the empiric therapy of bacterial meningitis. Treatment recommendations are based upon in vitro susceptibility and pharmacodynamic data, randomized trials in children, and accumulated clinical experience. </p><p></p><p class="bulletIndent1">Selected third-generation cephalosporins (ie, <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) are the beta-lactams of choice in the empiric treatment of meningitis. These drugs have consistent cerebrospinal fluid (CSF) penetration and potent activity against the major pathogens of bacterial meningitis, with the notable exceptions of <em>L. monocytogenes </em>and some penicillin-resistant strains of <em>S. pneumoniae </em>[<a href="#rid22">22</a>]. With the worldwide increase in the prevalence of penicillin-resistant pneumococci, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> should be added to ceftriaxone or cefotaxime as empiric treatment in countries where the prevalence of ceftriaxone resistance is &gt;1 percent (eg, the United States), until culture and susceptibility results are available [<a href="#rid2">2,26,27</a>]. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a>, a third-generation cephalosporin with broad in vitro activity against gram-negative bacteria including <em>Pseudomonas aeruginosa</em>, is much less active against penicillin-resistant pneumococci than <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid22">22</a>]. However, a fourth-generation cephalosporin, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, has been shown to be safe and therapeutically equivalent to cefotaxime for the treatment of bacterial meningitis in infants and children and is a suitable alternative to cefotaxime or ceftriaxone when broad activity against both pneumococcus and gram-negative bacteria, such as <em>P. aeruginosa,</em> is needed (eg, for immunocompromised) [<a href="#rid28">28</a>]. (See <a class="local">'Immunocompromised patients'</a> below.)</p><p></p><p class="bulletIndent1">Additional information on factors impacting the choice of agent is discussed above. (See <a class="local">'Antibiotic regimen'</a> above.)</p><p></p><p class="headingAnchor" id="H1089586095"><span class="h2">Sporadic community-acquired meningitis</span><span class="headingEndMark"> — </span>Antimicrobial therapy, along with adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, should be initiated as quickly as possible after the performance of the lumbar puncture (LP) or, if a CT scan of the head is to be performed before LP, as quickly as possible after blood cultures are obtained  (<a class="graphic graphic_algorithm graphicRef50114" href="/d/graphic/50114.html" rel="external">algorithm 1</a>) [<a href="#rid8">8,29,30</a>]. This section will review empiric antimicrobial regimens for community-acquired meningitis based upon the patient's age and other host factors. </p><p class="headingAnchor" id="H1437327070"><span class="h3">Antibiotic selection</span></p><p class="headingAnchor" id="H19"><span class="h4">No known immune deficiency</span><span class="headingEndMark"> — </span><em>S. pneumoniae</em>, <em>N. meningitidis</em>, and, less often, <em>H. influenzae </em>and group B <em>Streptococcus </em>are the most likely causes of community-acquired bacterial meningitis in otherwise healthy adults up to the age of 60 years [<a href="#rid25">25</a>]. Individuals over aged 50 years are also at increased risk of <em>L. monocytogenes </em>meningitis [<a href="#rid25">25,31</a>]. (See  <a class="medical medical_review" href="/d/html/1294.html" rel="external">"Epidemiology of community-acquired bacterial meningitis in adults", section on 'Incidence'</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p>Such patients, without evidence of renal insufficiency, should be treated empirically with the following regimen until culture and susceptibility data are available  (<a class="graphic graphic_table graphicRef71968 graphicRef60707" href="/d/graphic/71968.html" rel="external">table 3A-B</a>) [<a href="#rid8">8,26,27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> – 2 g intravenously (IV) every 12 hours.</p><p></p><p class="bulletIndent1"><strong>Or</strong></p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">Cefotaxime</a> (where available) – 2 g IV every four to six hours.</p><p></p><p class="bulletIndent1"><strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In countries with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> resistance rates &gt;1 percent, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> – 15 to 20 mg/kg IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60 mg/kg; adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL). Countries with resistance rates &gt;1 percent include the United States, Canada, China, Croatia, Greece, Italy, Mexico, Pakistan, Poland, Spain, and Turkey [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adults &gt;50 years of age, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> – 2 g IV every four hours.</p><p></p><p>A third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>) should be continued even if in vitro tests demonstrate <em>S. pneumoniae</em> with reduced susceptibility to third-generation cephalosporins (minimum inhibitory concentration ≥1 mcg/mL), since they may provide synergy with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> in this setting [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H20"><span class="h4">Immunocompromised patients</span><span class="headingEndMark"> — </span>For immunocompromised hosts, empiric antibiotic coverage must be directed against <em>L. monocytogenes</em> in addition to standard coverage for <em>S. pneumoniae, </em>regardless of age [<a href="#rid20">20</a>]. Such patients include those who are immunocompromised due to underlying conditions (eg, AIDS, lymphoma), as well as those receiving immunosuppressive agents such as cytotoxic chemotherapy, systemic glucocorticoids, and/or biologic immunomodulators (eg, TNF inhibitors). A more detailed discussion of risk factors for <em>Listeria</em> is found elsewhere. (See  <a class="medical medical_review" href="/d/html/1280.html" rel="external">"Epidemiology and pathogenesis of Listeria monocytogenes infection", section on 'Predisposing conditions'</a>.)</p><p>In addition to <em>Listeria</em> coverage, immunocompromised patients warrant expanded gram-negative coverage to include <em>P. aeruginosa</em>. Although it is unclear if all immunocompromised hosts need such coverage, we typically use the fourth-generation cephalosporin <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> or an antipseudomonal carbapenem in our initial regimen, instead of a third-generation cephalosporin that does not have activity against <em>Pseudomonas</em>. Antipseudomonal coverage is particularly important for those with neutropenia or impaired mucosal barriers (eg, from chemotherapy or severe burns), as well as for those at increased risk of nosocomial exposure. (See  <a class="medical medical_review" href="/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection", section on 'Epidemiology'</a>.)</p><p>An appropriate regimen for immunocompromised patients with normal renal function is  (<a class="graphic graphic_table graphicRef71968 graphicRef60707" href="/d/graphic/71968.html" rel="external">table 3A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> – 15 to 20 mg/kg IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60 mg/kg; adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL).</p><p></p><p class="bulletIndent1"><strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> – 2 g IV every four hours.</p><p></p><p class="bulletIndent1"><strong>plus either</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> – 2 g IV every eight hours.</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a> – 2 g IV every eight hours. If meropenem is used, initial treatment with <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> is not required, as meropenem has activity against <em>Listeria</em>. However, if <em>Listeria</em> is identified as the causative agent, the regimen should be modified to include ampicillin or penicillin (usually in combination with <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>). (See  <a class="medical medical_review" href="/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Alternatives to ampicillin or penicillin'</a>.) </p><p></p><p class="headingAnchor" id="H1856688194"><span class="h4">Beta-lactam allergy</span><span class="headingEndMark"> — </span>The approach to therapy in patients with beta-lactam allergies is challenging given the importance of early initiation of therapy and the crucial role of beta-lactam antibiotics in the treatment of bacterial meningitis. The choice of regimen must balance efficacy with the risk and severity of an allergic reaction. (See  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a> and  <a class="medical medical_review" href="/d/html/13535.html" rel="external">"Cephalosporin hypersensitivity: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1308900257"><span class="h5">Initial regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without severe beta-lactam allergy</strong> – In general, most patients who are labeled as allergic to penicillin are able to receive a cephalosporin such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> if immunocompromised)  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>). More detailed information on penicillin allergy is found elsewhere. (See  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions", section on 'Immediate versus delayed reactions'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a> should be used instead of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> in patients with isolated mild hives to a cephalosporin without other signs of anaphylaxis (especially if the reaction occurred in childhood and/or &gt;10 years ago) or mild delayed-type reactions to cephalosporins  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with severe beta-lactam allergy</strong> – When there is concern for a severe allergy to a penicillin or a cephalosporin (eg, anaphylaxis, Stevens Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], drug reaction with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis [AGEP]), an appropriate initial regimen for patients with normal renal function includes  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> – 15 to 20 mg/kg IV every 8 to 12 hours (not to exceed 2 g per dose or a total daily dose of 60 mg/kg; adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL).</p><p></p><p class="bulletIndent2">plus</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> – 400 mg IV once daily. In immunocompromised patients, <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> should be added to treat <em>Pseudomonas</em> as long as the patient does not have a serious allergy (eg, anaphylaxis, SJS/TEN, DRESS, AGEP) to aztreonam itself or an immediate or IgE-mediated allergy (eg, anaphylaxis, angioedema, hives/urticaria) to <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>. Ceftazidime and aztreonam share an R1 side chain group, and cross-reactivity between the two drugs is possible. (See  <a class="medical medical_review" href="/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Carbapenems and monobactams'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who require </strong><strong><em>Listeria</em></strong><strong> coverage</strong> – If <em>Listeria</em> coverage is required (patients &gt;50 years of age and/or immunocompromised hosts), <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can be initiated (5 mg/kg [based on the <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> component] IV every eight hours in patients with normal renal function) instead of <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>). However, there are limited data on the preferred dosing interval, and in case reports, the dose of trimethoprim-sulfamethoxazole has been administered anywhere from every 6 to every 12 hours [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> is used instead of a cephalosporin, additional treatment for <em>Listeria</em> is not required as meropenem has activity against <em>Listeria</em>. (See  <a class="medical medical_review" href="/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Alternatives to ampicillin or penicillin'</a>.) </p><p></p><p class="headingAnchor" id="H3826074850"><span class="h5">Continuing antibiotics</span><span class="headingEndMark"> — </span>After the initial dose of an antibiotic is administered, the regimen may be able to be modified. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a severe immediate allergy (eg, anaphylaxis) to a penicillin or cephalosporin may be able to tolerate <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, because rates of cross-reactivity between either penicillins or cephalosporins and carbapenems (eg, meropenem) are &lt;1 percent. However, in this setting, it should be administered via a test dose procedure. Because test dosing can introduce unnecessary delay in initiation of antibiotics, it is reasonable to administer <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> for the initial dose in an emergency room setting, and then transition to meropenem while awaiting the final culture results. Test dose protocols are reviewed separately. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Test dose procedure (graded challenge)'</a>.)</p><p></p><p class="bulletIndent1">Fluoroquinolones are not recommended as part of standard therapy unless unusual conditions, such as severe drug allergies or highly resistant organisms, are present. Although <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> has activity against drug-resistant pneumococcus and meningococcus, and fluoroquinolones achieve reasonably high CSF concentrations [<a href="#rid8">8,20</a>], these agents have not been extensively studied and there is only limited evidence of efficacy in animal models and in humans [<a href="#rid20">20,22</a>]. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Alternative agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an organism is suspected (eg, based on Gram strain) and the most appropriate treatment could not be initiated (eg, immediate reaction to cephalosporin) the patient should optimally be desensitized to the most effective beta-lactam if a drug allergy specialist is available and the type of past allergy is amenable to desensitization. However, the alternative regimen must be used until the desensitization can be performed. Desensitization protocols involve specialized knowledge and some risk and should be performed by drug allergy specialists. Following completion of treatment for bacterial meningitis, patients who have undergone desensitization should be referred for formal allergy assessment of their beta-lactam allergy label. This should ideally occur &gt;6 weeks after completion of treatment. (See  <a class="medical medical_review" href="/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a>.) </p><p></p><p class="bulletIndent1">Recommended treatment regimens for specific pathogens are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Regimens in patients with drug allergies'</a>.) </p><p></p><p class="headingAnchor" id="H23"><span class="h2">Empiric treatment during epidemics</span><span class="headingEndMark"> — </span>Epidemics of meningitis due to <em>N. meningitidis</em> are reported almost every year from sub-Saharan Africa. The empiric therapy recommended by the World Health Organization for meningococcal meningitis during epidemics is one or two intramuscular injections of long-acting <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> (oily suspension), although intramuscular <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is an acceptable alternative. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Considerations during epidemics in resource-limited settings'</a>.)</p><p class="headingAnchor" id="H1352766223"><span class="h1">TAILORING THERAPY</span><span class="headingEndMark"> — </span>Directed therapy against a specific organism is recommended when the clinical presentation and results of the cerebrospinal fluid Gram stain are unequivocal  (<a class="graphic graphic_table graphicRef75922" href="/d/graphic/75922.html" rel="external">table 3C</a>) or once the culture results are available  (<a class="graphic graphic_table graphicRef81209" href="/d/graphic/81209.html" rel="external">table 3D</a>) [<a href="#rid32">32</a>]. For patients with negative CSF culture, therapy is individualized depending on the remainder of the evaluation and clinical status.</p><p class="headingAnchor" id="H24"><span class="h2">Regimens based upon Gram stain</span><span class="headingEndMark"> — </span>Rather than empiric therapy, intravenous antimicrobial therapy should be directed at the presumed pathogen if the Gram stain is diagnostic  (<a class="graphic graphic_table graphicRef75922 graphicRef60707" href="/d/graphic/75922.html" rel="external">table 3B-C</a>) [<a href="#rid5">5</a>]. If the CSF findings are consistent with the diagnosis of acute bacterial meningitis but the Gram stain is negative, empiric antimicrobial therapy should be continued. If indicated, antimicrobial therapy should then be modified once the cerebrospinal fluid (CSF) culture and in vitro susceptibility studies are available  (<a class="graphic graphic_table graphicRef81209 graphicRef60707" href="/d/graphic/81209.html" rel="external">table 3B, 3D</a>). In addition, resistance patterns at a given hospital should be taken into account when choosing an empiric regimen.</p><p class="bulletIndent1"><span class="glyph">●</span>If gram-positive cocci are seen on the Gram stain of a patient with community-acquired meningitis, <em>S. pneumoniae</em> should be the suspected pathogen. <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> plus a third-generation cephalosporin (either <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>) should be administered. However, in the setting of neurosurgery or head trauma within the past month, a neurosurgical device, or a CSF leak, <em>S. aureus</em> and coagulase-negative staphylococci are more common, and therapy with vancomycin is warranted [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If gram-negative cocci are seen, <em>N. meningitidis</em> is the probable pathogen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-positive bacilli suggest <em>L. monocytogenes</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative bacilli usually represent Enterobacteriaceae (eg, <em>Klebsiella</em> spp, <em>E. coli</em>) in cases of community-acquired meningitis. </p><p></p><p>Additional information on regimens for patients with beta- lactam allergies is discussed above. (See <a class="local">'Beta-lactam allergy'</a> above.)</p><p class="headingAnchor" id="H25"><span class="h2">Positive CSF culture</span><span class="headingEndMark"> — </span>Directed therapy against a specific organism is recommended when the cultures are already positive [<a href="#rid32">32</a>]. If, on the other hand, empiric therapy is begun, the regimen should be adjusted, if necessary, once the culture results are available  (<a class="graphic graphic_table graphicRef81209" href="/d/graphic/81209.html" rel="external">table 3D</a>). Recommended dosages for use in patients with normal renal and hepatic function are shown in the table  (<a class="graphic graphic_table graphicRef60707" href="/d/graphic/60707.html" rel="external">table 3B</a>). The recommended treatment regimens for specific pathogens are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.)</p><p class="headingAnchor" id="H1780908458"><span class="h2">Negative CSF culture</span><span class="headingEndMark"> — </span>Cessation of antimicrobial therapy is <strong>not</strong> recommended in patients who have received prior or are receiving concurrent antimicrobial therapy with a negative CSF culture and who are suspected of having bacterial meningitis based on clinical and laboratory findings (eg, CSF pleocytosis). The choice of antimicrobial regimen and duration of administration should be individualized based on risk factors and likely infecting pathogens.</p><p>In patients in whom the diagnosis of community-acquired bacterial meningitis is uncertain (eg, possible viral meningitis), additional assessment is warranted. Review<strong> </strong>CSF parameters (eg, glucose, protein, WBC count); review or request CSF PCR analysis for viruses that may cause meningitis<strong> </strong> (<a class="graphic graphic_table graphicRef79745" href="/d/graphic/79745.html" rel="external">table 2</a>); and assess for alternative diagnoses. If the CSF PCR is positive for a viral etiology, then antibiotics can be discontinued. </p><p>Some clinicians calculate a risk score that has been used to identify patients at zero risk for having bacterial meningitis [<a href="#rid33">33</a>]. The following high-risk findings are considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Host factors (eg, age &gt;60 years, or intravenous drug use, or immunosuppressed)</p><p class="bulletIndent1"><span class="glyph">●</span>Exam (Glasgow Coma scale&lt;15, or vesicular or petechial rash, or aphasia, or focal motor deficits, or cranial nerve palsy, or seizure within one week</p><p class="bulletIndent1"><span class="glyph">●</span>CSF analysis (CSF glucose &lt;45mg/dL, or CSF protein &gt;100mg/dL or serum WBC &gt;12,000/mm<sup>3</sup>)</p><p></p><p>If none of these are present, it would be appropriate to discontinue antibiotics with careful monitoring. </p><p>In a case-control study in 111 patients with intracranial hemorrhage, the cell index had good discrimination capacity in identifying patients with culture confirmed cases [<a href="#rid34">34</a>]. Despite these findings, any decisions to discontinue antibiotics should be made with appropriate consultation.</p><p>Infections of CSF shunts and other devices are discussed separately. (See  <a class="medical medical_review" href="/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUPPORTIVE CARE</span></p><p class="headingAnchor" id="H27"><span class="h2">Fluid management</span><span class="headingEndMark"> — </span>Careful management of fluid and electrolyte balance is important, since both over- and under-hydration are associated with adverse outcomes.</p><p>A meta-analysis evaluated three randomized controlled trials of treatment of differing volumes of fluid (maintenance versus restricted fluid) given in the initial management of bacterial meningitis [<a href="#rid35">35</a>]. The largest trial was conducted in a setting with a high mortality rate. There was no significant difference between the two groups in number of deaths or acute severe or mild to moderate neurologic sequelae. However, when neurologic sequelae were defined further, there was a statistically significant difference in favor of the maintenance fluid group in regard to spasticity (relative risk [RR] 0.50, 95% CI 0.27-0.93), seizures at both 72 hours (RR 0.59, 95% CI 0.42-0.83) and 14 days (RR 0.19, 95% CI 0.04-0.88), and chronic severe neurologic sequelae at three months follow-up (RR 0.42, 95% CI 0.20-0.89). Thus, there is evidence that the use of intravenous maintenance fluids is preferred to restricted fluid intake in the first 48 hours in settings with high mortality rates and when patients present late. There is insufficient evidence to guide practice in other settings.</p><p class="headingAnchor" id="H28"><span class="h2">Reduction of intracranial pressure</span><span class="headingEndMark"> — </span>Patients with bacterial meningitis who have elevations of intracranial pressure (ICP) and who are stuporous or comatose may benefit from insertion of an ICP monitoring device [<a href="#rid36">36,37</a>]. Pressures exceeding 20 mmHg are abnormal and should be treated; there is also rationale for treating smaller pressure elevations (ie, above 15 mmHg) to avoid larger elevations that can lead to cerebral herniation and irreversible brainstem injury. (See  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'ICP monitoring'</a>.)</p><p>Methods to reduce ICP include elevating the head of the bed to 30º and hyperventilation to maintain PaCO<sub>2</sub> between 27 and 30 mmHg. Another method that has been evaluated for reducing ICP is oral administration of the hyperosmolar agent, glycerol. However, a randomized trial in adults with bacterial meningitis in Malawi (a resource-poor country with high HIV prevalence) was stopped early because planned interim analysis demonstrated increased mortality by day 40 in the glycerol group (63 versus 49 percent) [<a href="#rid38">38</a>]. The reason for this finding is unclear but might relate to an increased incidence of seizures in the patients who received glycerol. Another possible reason could be a rebound increase in ICP as the drug is eliminated, although ICP was not monitored in this trial. In contrast with this trial involving adults, some studies using glycerol have shown promising results in children with bacterial meningitis, although further data are needed before it can be recommended. (See  <a class="medical medical_review" href="/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Glycerol'</a>.)</p><p>In a study of 15 patients with bacterial meningitis in whom intracranial pressure was monitored, pressure was significantly lowered by a broad range of measures that utilized unconventional volume-targeted intracranial pressure management [<a href="#rid39">39</a>]. These included sedation, glucocorticoids, normal fluid and electrolyte homeostasis, blood transfusion, albumin infusion, decrease of mean arterial pressure, treatment with a prostacyclin analog, and eventually thiopental, ventriculostomy, and <a class="drug drug_general" data-topicid="9363" href="/d/drug information/9363.html" rel="external">dihydroergotamine</a>. In those not surviving their episode of bacterial meningitis, mean intracranial pressure was significantly higher. However, given that this was not a comparative trial, the results must be interpreted with caution.</p><p>In a prospective intervention-control comparison study of adult patients with acute bacterial meningitis, 53 patients were treated with conventional intensive care and 52 patients were given ICP-targeted treatment in the neuro-intensive care unit [<a href="#rid40">40</a>]. ICP-targeted treatment included cerebrospinal fluid (CSF) drainage using external ventricular catheters (48 patients), osmotherapy (21 patients), hyperventilation (13 patients), external cooling (9 patients), high doses of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (3 patients), and deep barbiturate sedation (2 patients), aiming to keep the ICP &lt;20 mmHg and cerebral perfusion pressure of &gt;50 mmHg. Mortality was significantly lower in the intervention group (10 versus 30 percent). However, this was not a randomized controlled trial and controls were identified retrospectively. Additional data are therefore needed.</p><p class="headingAnchor" id="H555247524"><span class="h2">Induced hypothermia</span><span class="headingEndMark"> — </span>There has been interest in evaluating induced hypothermia in patients with severe meningitis since there is evidence that it is beneficial in patients with global cerebral hypoxia following cardiac arrest (see  <a class="medical medical_review" href="/d/html/13838.html" rel="external">"Initial assessment and management of the adult post-cardiac arrest patient", section on 'Temperature management'</a>). However, more data are needed before therapeutic hypothermia can be recommended in patients with severe bacterial meningitis.</p><p>In an open-label multicenter randomized trial in 49 intensive care units in France, 98 comatose patients were randomly assigned to undergo induced hypothermia with a loading dose of 4°C cold <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and cooling to 32 to 34°C for 48 hours or standard care [<a href="#rid41">41</a>]. The trial was stopped early because of concerns about excess mortality in the induced hypothermia group compared with the control group (51 versus 31 percent; RR 1.99, 95% CI 1.05-3.77). At three months, 86 percent of patients in the hypothermia group had an unfavorable outcome (defined as a Glasgow Coma Scale score of 1 to 4) compared with 74 percent of those in the control group (RR 2.17, 95% CI 0.78-6.01). After adjustment for age, Glasgow Coma Scale score at inclusion, and the presence of septic shock at inclusion, mortality remained higher in the induced-hypothermia group, although the difference was not statistically significant (hazard ratio 1.76; 95% CI 0.89-3.45). The authors concluded that moderate hypothermia did not improve outcomes in patients with severe bacterial meningitis and that it may be harmful.</p><p>In a study of therapeutic hypothermia in adults with community-acquired bacterial meningitis, the incidence of hospital mortality (20 versus 49 percent) and adverse neurologic outcome (ie, a Glasgow outcome score 1 to 3; 44 versus 66 percent) were significantly lower in patients treated with therapeutic hypothermia [<a href="#rid42">42</a>]. However, the number of enrolled patients was small, and outcomes in this study of the 41 enrolled patients were compared with historical controls.</p><p class="headingAnchor" id="H29"><span class="h1">REPEAT CSF ANALYSIS</span><span class="headingEndMark"> — </span>There is limited utility to routine repeat lumbar puncture (LP) to assess the response to therapy in adults with bacterial meningitis. This was illustrated in a review of 165 adults with meningitis who underwent an end-of-treatment LP [<a href="#rid43">43</a>]. Wide ranges of glucose and protein concentrations and cell counts were found at the end of treatment in patients who were ultimately shown to be cured without further therapy. In addition, repeat cerebrospinal fluid (CSF) examination failed to detect relapse in the two patients who relapsed following treatment, and the CSF test results led to unnecessary testing in 13 patients with abnormal CSF findings at the end of therapy. The authors concluded that clinical signs of improvement were a better indicator of response to therapy than the results of CSF analysis after treatment had been completed.</p><p>Although not routinely recommended, there are settings in which repeat LP should be performed in patients with bacterial meningitis [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>When there is no evidence of improvement by 48 hours after the initiation of appropriate therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two to three days after the initiation of therapy of meningitis due to microorganisms resistant to standard antimicrobial agents (eg, penicillin-resistant pneumococcal infection), especially for those who are not responding as expected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent fever for more than eight days without another explanation</p><p></p><p>Repeat CSF cultures should be sterile. For patients in whom repeat cultures are positive despite appropriate therapy with parenteral antibiotic therapy, administration of intrathecal (or intraventricular) antibiotics may be considered [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H30"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>There is an appreciable mortality rate associated with bacterial meningitis even with the administration of appropriate antibiotics.</p><p class="headingAnchor" id="H31"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Despite the decreased mortality of meningitis with the advent of effective antibiotics, mortality from meningitis still remains significant. The global burden of disease study in 2016 documented that meningitis caused 318,000 deaths and 21,866,000 disability-adjusted life years annually in the world [<a href="#rid45">45</a>].</p><p>The mortality rate of bacterial meningitis increases linearly with increasing age. In a United States population-based surveillance study between 2003 and 2007, the case-fatality rate in adults was 16.4 percent; among patients between 18 and 34 years of age, the case-fatality rate was 8.9 percent compared with 22.7 percent in patients ≥65 years of age [<a href="#rid46">46</a>]. The overall case-fatality rate did not change significantly between 1998 to 1999 and 2006 to 2007.</p><p>Outcomes also vary depending upon the organism. The following observations from different time periods illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 493 episodes of bacterial meningitis in 445 adults seen at a single center in the United States from 1962 to 1988, the overall mortality rate was 25 percent and did not vary over the course of the study [<a href="#rid6">6</a>]. The mortality rate was higher with health care-associated compared with community-acquired infection (35 versus 25 percent) and was higher with infection due to <em>S. pneumoniae</em> and <em>L. monocytogenes </em>compared with <em>N. meningitidis</em> (28 and 32 versus 10 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 248 patients seen in 1995 in acute care hospitals in 22 counties in four states in the United States, the mortality rate was highest with <em>S. pneumoniae</em> and <em>L. monocytogenes </em>(21 and 15 percent, respectively) and lowest with <em>N. meningitidis</em> (3 percent) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report from the Netherlands evaluated 696 cases of community-acquired acute bacterial meningitis seen between 1998 and 2002 [<a href="#rid48">48</a>]. The overall mortality rate was significantly higher with pneumococcal compared with meningococcal meningitis (30 versus 7 percent). In addition, an unfavorable outcome was six times more common with pneumococcal meningitis, even after adjustment for other clinical predictors.</p><p></p><p>Mortality rates of bacterial meningitis may be elevated in settings with a high prevalence of HIV infection. In a cohort study of patients undergoing lumbar puncture in Botswana, among whom 72 percent had documented HIV infection, the 10-week and 1-year mortality rates among the 238 patients with culture-confirmed pneumococcal meningitis were 47 percent and 49 percent, respectively [<a href="#rid49">49</a>]. The median CD4 count was 136 cells/microL and 45 percent of the cohort was on antiretroviral therapy.</p><p>The use of adjunctive <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is associated with a reduction in mortality in selected patients with bacterial meningitis. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Neurologic complications</span><span class="headingEndMark"> — </span>Neurologic complications are not uncommon in adults with bacterial meningitis. In a review of 493 episodes of bacterial meningitis in adults, for example, 28 percent of community-acquired episodes resulted in one or more neurologic complications [<a href="#rid6">6</a>]. The neurologic complications of bacterial meningitis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Increased intracranial pressure and cerebral edema</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Focal neurologic deficits (eg, cranial nerve palsy, hemiparesis)</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrovascular abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss</p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual impairment</p><p></p><p>These are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1291.html" rel="external">"Neurologic complications of bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Prediction of risk</span><span class="headingEndMark"> — </span>Baseline features can be used to estimate the individual patient's risk for an adverse outcome. A prognostic model was derived from a cohort of 176 adults and then validated in another cohort of 93 patients [<a href="#rid5">5</a>]. In-hospital mortality was 27 percent, and 9 percent had a neurologic deficit at discharge. Three baseline clinical features (hypotension, altered mental status, and seizures) were independently associated with an adverse outcome (defined as in-hospital death or neurologic deficit at discharge) and stratified the patients into three risk groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (no clinical risk factors) – 9 percent adverse outcome</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (one clinical risk factor) – 33 percent adverse outcome</p><p class="bulletIndent1"><span class="glyph">●</span>High risk (two or three risk factors) – 56 percent adverse outcome</p><p></p><p>An additional risk factor for an adverse outcome in this report was advancement from low or intermediate risk to high risk in the emergency department prior to the administration of antibiotics. Although this finding supports the recommendation to avoid delays in antimicrobial therapy in patients with suspected bacterial meningitis, it is also consistent with the hypothesis that severely ill patients at the start may have an adverse outcome regardless of the timing of initial therapy [<a href="#rid50">50</a>].</p><p>In a review and external validation study of nine risk scores developed to predict outcomes in patients with bacterial meningitis, pneumococcal meningitis, and invasive meningococcal disease, none could be recommended for use in managing individual patients [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H3961973258"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104441.html" rel="external">"Society guideline links: Bacterial meningitis in adults"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16956.html" rel="external">"Patient education: Bacterial meningitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4003.html" rel="external">"Patient education: Vaccines for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Community-acquired bacterial meningitis is a medical emergency. The most important initial management issues are avoiding a delay in administering antimicrobial therapy and choosing an effective drug regimen. The mortality rate of untreated disease approaches 100 percent and, even with optimal therapy, there can be a high failure rate. (See <a class="local">'General principles of therapy'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – The initial evaluation should include two sets of blood cultures and a lumbar puncture (LP)  (<a class="graphic graphic_algorithm graphicRef50114" href="/d/graphic/50114.html" rel="external">algorithm 1</a>). An important early decision relates to whether a head CT should be performed prior to LP. (See <a class="local">'Pretreatment testing'</a> above.)</p><p></p><p class="bulletIndent1">If possible, crucial information (eg, serious drug allergies, recent exposure to an individual with meningitis) should also be obtained before antibiotic treatment of presumed bacterial meningitis is instituted. (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antimicrobial therapy</strong> – We recommend that antimicrobial therapy be initiated immediately after the performance of the LP or, if a CT scan is going to be performed before the LP, immediately after blood cultures are obtained (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Avoidance of delay'</a> above.)</p><p></p><p class="bulletIndent1">The approach to regimen selection in patients with suspected bacterial meningitis is directed at the most likely bacteria based on the patient's age and other host factors  (<a class="graphic graphic_table graphicRef71968 graphicRef60707" href="/d/graphic/71968.html" rel="external">table 3A-B</a> and <a class="graphic graphic_table graphicRef120657" href="/d/graphic/120657.html" rel="external">table 4</a>). (See <a class="local">'Avoidance of delay'</a> above and <a class="local">'Empiric regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to administer </strong><a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> – For adults in resource-rich settings with suspected community-acquired bacterial meningitis due to an unknown organism, we recommend administration of dexamethasone in addition to antimicrobial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Adjunctive dexamethasone should be given shortly before or at the same time as the first dose of antibiotics, when indicated. Dexamethasone should be only continued if the CSF Gram stain and/or the CSF or blood cultures reveal <em>S. pneumoniae</em>.<em> </em></p><p></p><p class="bulletIndent1">The indications for <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> for patients with suspected or confirmed bacterial meningitis in resource-limited settings depend on the patient population and are discussed in detail elsewhere. (See <a class="local">'When to administer dexamethasone'</a> above and  <a class="medical medical_review" href="/d/html/1299.html" rel="external">"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tailoring therapy</strong> – Once the CSF Gram stain results are available, the antimicrobial regimen should be tailored to cover the most likely pathogen. If the CSF findings are consistent with the diagnosis of acute bacterial meningitis but the Gram stain is negative, empiric antibiotic therapy should still be continued. (See <a class="local">'Regimens based upon Gram stain'</a> above.)</p><p></p><p class="bulletIndent1">The antibiotic regimen should be modified further, when indicated, based on the CSF culture and susceptibility results. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Swartz MN. Bacterial meningitis--a view of the past 90 years. N Engl J Med 2004; 351:1826.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. Nat Rev Dis Primers 2016; 2:16074.</a></li><li><a class="nounderline abstract_t">Oordt-Speets AM, Bolijn R, van Hoorn RC, et al. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS One 2018; 13:e0198772.</a></li><li><a class="nounderline abstract_t">de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.</a></li><li><a class="nounderline abstract_t">Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862.</a></li><li><a class="nounderline abstract_t">Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.</a></li><li><a class="nounderline abstract_t">Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA 1999; 282:175.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727.</a></li><li><a class="nounderline abstract_t">Park N, Nigo M, Hasbun R. Comparison of Four International Guidelines on the Utility of Cranial Imaging Before Lumbar Puncture in Adults with Bacterial Meningitis. Clin Neuroradiol 2022; 32:857.</a></li><li><a class="nounderline abstract_t">Salazar L, Hasbun R. Cranial Imaging Before Lumbar Puncture in Adults With Community-Acquired Meningitis: Clinical Utility and Adherence to the Infectious Diseases Society of America Guidelines. Clin Infect Dis 2017; 64:1657.</a></li><li><a class="nounderline abstract_t">Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis 2016; 16:339.</a></li><li><a class="nounderline abstract_t">Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006; 34:2758.</a></li><li><a class="nounderline abstract_t">Lepur D, Barsić B. Community-acquired bacterial meningitis in adults: antibiotic timing in disease course and outcome. Infection 2007; 35:225.</a></li><li><a class="nounderline abstract_t">Proulx N, Fréchette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98:291.</a></li><li><a class="nounderline abstract_t">Køster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect 2008; 57:449.</a></li><li><a class="nounderline abstract_t">Bodilsen J, Dalager-Pedersen M, Schønheyder HC, Nielsen H. Time to antibiotic therapy and outcome in bacterial meningitis: a Danish population-based cohort study. BMC Infect Dis 2016; 16:392.</a></li><li><a class="nounderline abstract_t">Nigrovic LE, Malley R, Macias CG, et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics 2008; 122:726.</a></li><li><a class="nounderline abstract_t">Rogers T, Sok K, Erickson T, et al. Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis. Open Forum Infect Dis 2019; 6:ofz050.</a></li><li><a class="nounderline abstract_t">Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708.</a></li><li><a class="nounderline abstract_t">Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297:410.</a></li><li><a class="nounderline abstract_t">Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 2004; 18:581.</a></li><li><a class="nounderline abstract_t">Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23:467.</a></li><li><a class="nounderline abstract_t">Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14:813.</a></li><li><a class="nounderline abstract_t">Brouwer MC, van de Beek D. Epidemiology of community-acquired bacterial meningitis. Curr Opin Infect Dis 2018; 31:78.</a></li><li><a class="nounderline abstract_t">van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22 Suppl 3:S37.</a></li><li><a class="nounderline abstract_t">McGill F, Heyderman RS, Michael BD, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect 2016; 72:405.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 2012; 380:1684.</a></li><li><a class="nounderline abstract_t">van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012; 380:1693.</a></li><li><a class="nounderline abstract_t">Charlier C, Perrodeau É, Leclercq A, et al. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infect Dis 2017; 17:510.</a></li><li><a class="nounderline abstract_t">Hasbun R. Update and advances in community acquired bacterial meningitis. Curr Opin Infect Dis 2019; 32:233.</a></li><li><a class="nounderline abstract_t">Hasbun R, Bijlsma M, Brouwer MC, et al. Risk score for identifying adults with CSF pleocytosis and negative CSF Gram stain at low risk for an urgent treatable cause. J Infect 2013; 67:102.</a></li><li><a class="nounderline abstract_t">Montes K, Jenkinson H, Habib OB, et al. Corrected white blood cell count, cell index, and validation of a clinical model for the diagnosis of health care-associated ventriculitis and meningitis in adults with intracranial hemorrhage. Clin Neurol Neurosurg 2019; 178:36.</a></li><li><a class="nounderline abstract_t">Oates-Whitehead RM, Maconochie I, Baumer H, Stewart ME. Fluid therapy for acute bacterial meningitis. Cochrane Database Syst Rev 2005; :CD004786.</a></li><li><a class="nounderline abstract_t">van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354:44.</a></li><li><a class="nounderline abstract_t">Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007; 9:308.</a></li><li><a class="nounderline abstract_t">Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011; 11:293.</a></li><li><a class="nounderline abstract_t">Lindvall P, Ahlm C, Ericsson M, et al. Reducing intracranial pressure may increase survival among patients with bacterial meningitis. Clin Infect Dis 2004; 38:384.</a></li><li><a class="nounderline abstract_t">Glimåker M, Johansson B, Halldorsdottir H, et al. Neuro-intensive treatment targeting intracranial hypertension improves outcome in severe bacterial meningitis: an intervention-control study. PLoS One 2014; 9:e91976.</a></li><li><a class="nounderline abstract_t">Mourvillier B, Tubach F, van de Beek D, et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA 2013; 310:2174.</a></li><li><a class="nounderline abstract_t">Kutleša M, Lepur D, Baršić B. Therapeutic hypothermia for adult community-acquired bacterial meningitis-historical control study. Clin Neurol Neurosurg 2014; 123:181.</a></li><li><a class="nounderline abstract_t">Durack DT, Spanos A. End-of-treatment spinal tap in bacterial meningitis. Is it worthwhile? JAMA 1982; 248:75.</a></li><li><a class="nounderline abstract_t">Ziai WC, Lewin JJ 3rd. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol 2009; 22:277.</a></li><li><a class="nounderline abstract_t">GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18:459.</a></li><li><a class="nounderline abstract_t">Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016.</a></li><li><a class="nounderline abstract_t">Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.</a></li><li><a class="nounderline abstract_t">van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.</a></li><li><a class="nounderline abstract_t">Tenforde MW, Mokomane M, Leeme TB, et al. Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. Lancet Infect Dis 2019; 19:740.</a></li><li><a class="nounderline abstract_t">Kilpi T, Anttila M, Kallio MJ, Peltola H. Length of prediagnostic history related to the course and sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 1993; 12:184.</a></li><li><a class="nounderline abstract_t">Bijlsma MW, Brouwer MC, Bossuyt PM, et al. Risk scores for outcome in bacterial meningitis: Systematic review and external validation study. J Infect 2016; 73:393.</a></li></ol></div><div id="topicVersionRevision">Topic 1290 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509815" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bacterial meningitis--a view of the past 90 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27808261" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889859" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global etiology of bacterial meningitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432041" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dexamethasone in adults with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867727" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416268" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute bacterial meningitis in adults. A review of 493 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411200" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The rational clinical examination. Does this adult patient have acute meningitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742046" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Computed tomography of the head before lumbar puncture in adults with suspected meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35181803" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of Four International Guidelines on the Utility of Cranial Imaging Before Lumbar Puncture in Adults with Bacterial Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369295" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cranial Imaging Before Lumbar Puncture in Adults With Community-Acquired Meningitis: Clinical Utility and Adherence to the Infectious Diseases Society of America Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26652862" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16915106" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646915" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Community-acquired bacterial meningitis in adults: antibiotic timing in disease course and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760921" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antibiotic treatment delay and outcome in acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27507415" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Time to antibiotic therapy and outcome in bacterial meningitis: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18829794" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899767" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041103" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/882110" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A pharmacologic evaluation of penicillin in children with purulent meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15308277" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antimicrobial agents in the treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610819" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104307" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29176349" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology of community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27062097" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : ESCMID guideline: diagnosis and treatment of acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26845731" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203777" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23141617" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dilemmas in the diagnosis of acute community-acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23141618" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Advances in treatment of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28139432" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31021955" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Update and advances in community acquired bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619080" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk score for identifying adults with CSF pleocytosis and negative CSF Gram stain at low risk for an urgent treatable cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30708338" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Corrected white blood cell count, cell index, and validation of a clinical model for the diagnosis of health care-associated ventriculitis and meningitis in adults with intracranial hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034949" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fluid therapy for acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394301" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Community-acquired bacterial meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618551" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neurocritical care of patients with central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334262" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727209" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reducing intracranial pressure may increase survival among patients with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24667767" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neuro-intensive treatment targeting intracranial hypertension improves outcome in severe bacterial meningitis: an intervention-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24105303" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Induced hypothermia in severe bacterial meningitis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24981517" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Therapeutic hypothermia for adult community-acquired bacterial meningitis-historical control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087096" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : End-of-treatment spinal tap in bacterial meningitis. Is it worthwhile?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19434796" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Improving the role of intraventricular antimicrobial agents in the management of meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879893" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21612470" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bacterial meningitis in the United States, 1998-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395430" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bacterial meningitis in the United States in 1995. Active Surveillance Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509818" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical features and prognostic factors in adults with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250824" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8451093" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Length of prediagnostic history related to the course and sequelae of childhood bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27519619" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk scores for outcome in bacterial meningitis: Systematic review and external validation study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
